HBMN:SWX
HBM Healthcare Investments AG
CHF 223.00
arrow_upward
+0.22%(+0.50) 1H
18 Nov, 5:31:03 PTG GMT+1 · CHF
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk HBMN...
Buka
CHF 222.50
Tinggi
CHF 223.50
Rendah
CHF 219.50
Permodalan Pasaran
1.48B
Purata volum
5.81K
Volum
9.03K
Dividen
4.04%
Dividen suku tahunan
CHF 2.25
Tarikh tanpa dividen
17 Jun 2026
Nisbah H/P
4.19
tgi 52 mgu
CHF 258.00
rdh 52 mgu
CHF 198.60
EPS
CHF 53.19
Syer tertunggak
6.62J
Buka
CHF 222.50
Tinggi
CHF 223.50
Rendah
CHF 219.50
Permodalan Pasaran
1.48B
Purata volum
5.81K
Volum
9.03K
Dividen
4.04%
Dividen suku tahunan
CHF 2.25
Tarikh tanpa dividen
17 Jun 2026
Nisbah H/P
4.19
tgi 52 mgu
CHF 258.00
rdh 52 mgu
CHF 198.60
EPS
CHF 53.19
Syer tertunggak
6.62J
Cerita berita
Daripada sumber web dan rakan kongsi berita
The Motley Fool
·
59 minit lalu
If You'd Invested $1,000 in an S&P 500 ETF Ahead of the Dot-Com Bubble, Here's What You'd Have Today
ChartMill
·
1 jam lalu
S&P 500 Top Movers: Gainers and Losers in the Nov. 18, 2026 US Session
BigGo Finance
·
6 jam lalu
UBS Sets S&P 500 End-2027 Target at 8,200, 12% Above Current Level, Assuming Continued AI Investment
StoneX
·
7 jam lalu
S&P 500 Quietly Shrugs Off the Bitcoin and Silver Selloff
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Perihal HBM Healthcare Investments AG
CEO-
Pekerja-
Diasaskan12 Jul 2001
Ibu pejabatZug, Zug, Switzerland
SektorFinancials
Industri-
Laman webhbmhealthcare.com